Do Traders Think ORIC Pharmaceuticals Inc (ORIC) Can Keep Climbing Monday?

Overall market sentiment has been down on ORIC Pharmaceuticals Inc (ORIC) stock lately. ORIC receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

ORIC Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ORIC!

See Full ORIC Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ORIC Stock Today?

ORIC Pharmaceuticals Inc (ORIC) stock is up 5.63% while the S&P 500 has fallen -0.9% as of 10:43 AM on Monday, Apr 25. ORIC is up $0.21 from the previous closing price of $3.73 on volume of 77,502 shares. Over the past year the S&P 500 is up 1.10% while ORIC has fallen -83.89%. ORIC lost -$2.07 per share in the over the last 12 months.

More About ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101, ORIC-944, ORIC-114, and ORIC-533. Click Here to get the full Stock Report for ORIC Pharmaceuticals Inc stock.